Vedanta Biosciences is a clinical-stage biotechnology company developing a new category of therapies for immune-mediated diseases based on rationally-defined consortia of human microbiome-derived bacteria. The company's lead product candidate, VE303, is a live biotherapeutic product (LBP) consisting of a defined consortium of bacteria designed to induce immune tolerance and prevent the onset of recurrent Clostridioides difficile infection (rCDI). Vedanta Biosciences was founded in 2010 by PureTech Health and a team of world-renowned experts in immunology and microbiology from Harvard Medical School and MIT. The company is headquartered in Cambridge, Massachusetts.